Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/atorvastatin/valsartan - HK inno.N

Next Previous
Drug Profile

Amlodipine/atorvastatin/valsartan - HK inno.N

Alternative Names: Atorvastatin/amlodipine/valsartan; CJ 30061; IN-C008; Valsartan/atorvastatin/amlodipine

Latest Information Update: 28 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CJ HealthCare
  • Developer HK inno.N
  • Class Amides; Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Dihydropyridines; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Hyperlipidaemia; Hypertension

Most Recent Events

  • 28 Nov 2022 Amlodipine/atorvastatin/valsartan is still in preregistration for Hypertension in South Korea (HK inno.N pipeline, July 2022)
  • 28 Sep 2020 Preregistration for Hyperlipidaemia in South Korea (PO) prior to September 2020 (HK inno.N pipeline, September 2020)
  • 28 Sep 2020 Preregistration for Hypertension in South Korea (PO) prior to September 2020 (HK inno.N pipeline, September 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top